# OnCo record paper-nala-j-clin-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nala-j-clin-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nala-j-clin-oncol-2020" ;
  schema:name "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial"@en ;
  schema:description "Published report from the NALA trial registered as NCT01808573, in Journal of Clinical Oncology (2020), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nala-j-clin-oncol-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.20.00147>, <https://pubmed.ncbi.nlm.nih.gov/32678716/>, <https://europepmc.org/article/MED/32678716>, <https://clinicaltrials.gov/study/NCT01808573> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1200/jco.20.00147> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Saura C, Oliveira M, Feng YH, et al." ;
  onco:trials <https://onco.cc/trials/nala/> ;
  onco:journals <https://onco.cc/journals/jco/> .